Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma

Figures & data

Table 1 Molecular drivers in melanoma

Anatomical site of origin	Somatic gene mutation	Approximate frequency (%)	References
Skin
With chronic sun damage	BRAF	10	^Citation15
	NRAS	15
Without chronic sun damage	BRAF	60	^Citation15
	NRAS	20
Acral surfaces	KIT	6–40	^Citation16,Citation17,Citation72
Mucosal surfaces	KIT	15–40	^Citation16,Citation17,Citation72
Uveal	GNAQ	22–45	^Citation18
	GNA11	30–60

Table 2 Summary of BRIM trial results

Phase	Patient number	Patient population	Response rate (%)	Median PFS (months)	Median OS (months)	References
I/II	32a	Advanced melanoma; previous systemic therapy	56b	>7	12.6	^Citation42
II	132	Advanced melanoma; previous systemic therapy	53	6.8	15.9	^Citation45
II	675 (336 treated with vemurafenib)	Advanced melanoma; no prior systemic therapy	48	5.3c HR 0.26 favoring vemurafenib	13.2c HR 0.44 favoring vemurafenib	^Citation13

Notes:

a With BRAF mutations;

b by independent assessment;

c from the Summary of Product Characteristics, European Medicines Agency.

Abbreviations: HR, hazards ratio; PFS, progression-free survival; OS, overall survival.

CurtinJAFridlyandJKageshitaTDistinct sets of genetic alterations in melanomaN Engl J Med20053532135214716291983

 PubMed Web of Science ®Google Scholar

CurtinJABusamKPinkelDSomatic activation of KIT in distinct subtypes of melanomaJ Clin Oncol2006244340434616908931

 PubMed Web of Science ®Google Scholar

BeadlingCJacobson-DunlopEHodiFSKIT gene mutations and copy number in melanoma subtypesClin Cancer Res2008146821682818980976

 PubMed Web of Science ®Google Scholar

HandoliasDHamiltonALSalemiRClinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KITBr J Cancer20101021219122320372153

 PubMed Web of Science ®Google Scholar

Van RaamsdonkCDGriewankKGCrosbyMBMutations in GNA11 in uveal melanomaN Engl J Med20103632191219921083380

 PubMed Web of Science ®Google Scholar

FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaN Engl J Med201036380981920818844

 PubMed Web of Science ®Google Scholar

SosmanJAKimKBSchuchterLSurvival in BRAF V600- mutant advanced melanoma treated with vemurafenibN Engl J Med201236670771422356324

 PubMed Web of Science ®Google Scholar

ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med20113642507251621639808

 PubMed Web of Science ®Google Scholar